Financial Performance - The company's revenue for Q3 2023 was ¥75,661,205.43, representing a 4.04% increase year-over-year, while the year-to-date revenue reached ¥240,653,628.05, up 33.43% compared to the same period last year[5]. - Net profit attributable to shareholders for Q3 2023 was ¥23,490,906.05, a decrease of 29.03% year-over-year, with a year-to-date net profit of ¥77,311,464.53, an increase of 12.17%[5]. - The basic and diluted earnings per share for Q3 2023 were both ¥0.4698, reflecting a 29.03% decline compared to the same period last year[5]. - The company's operating revenue for the first nine months of 2023 reached ¥240.65 million, a 33.43% increase compared to ¥180.36 million in the same period of 2022, driven by sufficient orders[12]. - Total operating revenue for the period reached CNY 240,653,628.05, an increase of 33.4% compared to CNY 180,362,132.13 in the previous period[24]. - Net profit attributable to shareholders was CNY 77,311,464.53, representing a 12.5% increase from CNY 68,926,068.57 year-over-year[25]. - Basic and diluted earnings per share were both CNY 1.5462, compared to CNY 1.3785 in the previous period[26]. Assets and Liabilities - Total assets as of September 30, 2023, were ¥1,518,196,536.60, a significant increase of 275.23% from the end of the previous year[5]. - As of September 30, 2023, the total assets of Anhui Wanbang Pharmaceutical Technology Co., Ltd. reached CNY 1,518,196,536.60, a significant increase from CNY 404,600,418.67 at the beginning of the year[21]. - The total liabilities of the company were CNY 84,967,162.79, compared to CNY 72,983,405.88 previously, reflecting an increase of approximately 16.4%[22]. - The equity of the company increased to CNY 66,666,667.00 from CNY 50,000,000.00, showing a growth of 33.33%[22]. Cash Flow - The company's cash flow from operating activities for the year-to-date period was ¥49,475,182.02, showing a slight increase of 0.49%[5]. - The net cash flow from financing activities was ¥1.03 billion, attributed to funds raised from stock issuance during the reporting period[13]. - Cash and cash equivalents increased by 3290.76% to ¥865.52 million, also due to the funds raised from stock issuance[13]. - The total cash inflow from financing activities was 1,052,940,021.04 CNY, with no cash inflow recorded in the previous year[27]. - The net cash flow from financing activities reached 1,034,075,946.06 CNY, a substantial increase from 0.00 CNY in Q3 2022[27]. - The total cash and cash equivalents at the end of Q3 2023 amounted to 1,051,675,742.41 CNY, up from 186,999,266.54 CNY at the end of Q3 2022[27]. - The net increase in cash and cash equivalents for Q3 2023 was 865,520,991.91 CNY, compared to 25,525,905.77 CNY in the same quarter last year[27]. Research and Development - The company has increased its R&D investment, with development expenditures rising by 94.61% to ¥4,130,828.47[10]. - Research and development expenses surged by 98.48% to ¥23.89 million from ¥12.04 million, reflecting the company's commitment to increasing R&D investment[12]. - Research and development expenses increased to CNY 23,892,759.21, a rise of 98.5% from CNY 12,037,800.13 in the previous period[24]. Inventory and Other Assets - The company's inventory increased by 276.62% to ¥1,672,179.34, attributed to ongoing projects by subsidiaries[10]. - The company's inventory rose to CNY 1,672,179.34 from CNY 444,001.10, marking an increase of approximately 276%[21]. - Non-current assets totaled CNY 179,625,574.91, up from CNY 118,384,613.77, indicating a growth of about 51.7%[22]. Shareholder Information - The top shareholder, Tao Chunlei, holds 39.64% of the shares, with a total of 26,427,800 shares[15]. - The total number of ordinary shareholders at the end of the reporting period was 24,797[15]. - The company reported a total of 50,861,136 shares, including 861,136 shares under lock-up after the initial public offering[19]. - The company has plans to release locked-up shares on September 25, 2024, and September 25, 2026, for various shareholders[18]. Other Financial Metrics - The company reported a 90.85% increase in credit impairment losses, amounting to -¥1.15 million, primarily due to an increase in accounts receivable[12]. - The company experienced a 50.81% decrease in other income, totaling ¥4.30 million, due to a reduction in government subsidies related to income[12]. - Other income for the period was CNY 4,297,585.21, down from CNY 8,736,509.09 in the previous period[24]. - The company recorded a financial asset impairment loss of CNY 1,570,905.04, compared to CNY 838,913.03 in the previous period[25]. Investment Activities - The net cash flow from investing activities significantly decreased by 819.69%, amounting to -¥218.03 million, primarily due to an increase in transferable large-denomination certificates[13]. - The company reported a total investment cash outflow of 346,787,396.91 CNY in Q3 2023, compared to 875,113,444.15 CNY in the same period last year[27]. - The cash paid for investment activities was 277,637,164.41 CNY, a decrease from 848,978,812.52 CNY in Q3 2022[27]. - The company did not report any cash payments related to the acquisition of subsidiaries or other business units in Q3 2023[27]. Audit Status - The company has not yet audited the Q3 2023 report, indicating that the figures are preliminary[28].
万邦医药(301520) - 2023 Q3 - 季度财报